Plain-English translation of NCT07654426 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication designed to protect the heart, can safely prevent heart damage when added to standard lymphoma chemotherapy. People with diffuse large B-cell lymphoma who have risk factors for heart problems (such as a history of heart issues or previous heart-damaging cancer treatment) are invited to join. Half the participants will receive the protective medication alongside their chemotherapy, while the other half will receive a placebo to see which approach works better.
Some chemotherapy drugs used to treat lymphoma can damage the heart over time, especially in patients who already have heart risk factors. Researchers want to find out if this medication can prevent that heart damage and make chemotherapy safer for vulnerable patients.
You likely qualify if…
You likely don't qualify if…
You will have an initial screening visit with heart and blood tests, then begin chemotherapy with either the protective medication or a placebo—neither you nor your doctor will know which you're receiving. Throughout your treatment cycles (lasting several weeks to months depending on your plan), you'll have regular clinic visits, heart monitoring tests like echocardiograms and EKGs, and blood work. After chemotherapy ends, you'll return for follow-up visits at 3 months and 1 year, then annually for several more years to check your heart health and overall recovery.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States